In 2024, the World Health Organization (WHO) reported that noncommunicable diseases (NCDs) account for approximately 75% of all deaths worldwide.
For pharmaceutical and biotech companies working in CVRMs, understanding future disease burden is essential to long-term strategy in order to inform decisions regarding where, when and how to invest resources for maximum impact of return. This is important when developing therapeutic interventions, but also for identifying where those interventions can have the greatest impact, and for making the case to act sooner.
In this context, epidemiological modelling is playing a growing role in evidence generation.
Chronic Kidney Disease (CKD) affects more than 10% of the population worldwide and is often associated with other conditions such as diabetes and hypertension. However, rare kidney diseases, although individually rare, collectively exert a notable impact on kidney health – accounting for an estimated 5–10% of CKD cases.
Despite their impact, rare kidney diseases often remain underdiagnosed and under-recognised within CKD care and policy frameworks. This raises critical questions: Why do so many rare kidney conditions go undiagnosed? Could rare kidney diseases account for more CKD cases than previously thought? And what would earlier diagnosis and targeted intervention mean for patients, health systems, and payers? This article aims to address these questions.
Chronic kidney disease (CKD) is a major global health issue – affecting an estimated 1 in 10 people – yet it is frequently overlooked on health agendas worldwide. In its early stages, CKD is often asymptomatic, and many individuals are unaware that they have CKD until the disease has progressed to later stages, where it becomes harder and more costly to treat – with patients facing the prospect of dialysis or kidney transplant. This makes early CKD detection critical to improving patient outcomes and reducing the growing health and economic burden of CKD worldwide. Recognising this, the World Kidney Day campaign this year is centred around the theme: “Detect early, protect kidney health.”
As part of AstraZeneca’s Accelerate Change Together (ACT) on CKD programme to drive chronic kidney disease (CKD) change across the healthcare ecosystem, the Inside CKD project stream projected the clinical and economic burden of CKD from 2022 to 2027 across 31 countries and regions. The results have recently been compiled into a comprehensive portal on the Inside CKD website.
In partnership with AstraZeneca, HealthLumen has recently published two publications that project the clinical (1) and economic (2) burden of Chronic Kidney Disease (CKD) and Kidney Replacement Therapy (KRT) into the future, as part of the “Inside CKD” programme, which contributes to the major strategic initiative at AstraZeneca dedicated to driving better patient outcomes. From […]
When you need a future-facing decision engine for big, real world population health questions, we are the people to turn to.
Solutions